DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1

Abstract Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES-1 inhibitor identified through tradition...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuo Zhou, Ziyuan Zhou, Kai Ding, Yaxia Yuan, Charles Loftin, Fang Zheng, Chang-Guo Zhan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6b1699a55ab84411a029ef331c7ca2c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6b1699a55ab84411a029ef331c7ca2c5
record_format	dspace
spelling	oai:doaj.org-article:6b1699a55ab84411a029ef331c7ca2c52021-12-02T17:45:21ZDREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-110.1038/s41598-020-67283-02045-2322https://doaj.org/article/6b1699a55ab84411a029ef331c7ca2c52020-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-67283-0https://doaj.org/toc/2045-2322Abstract Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES-1 inhibitor identified through traditional drug discovery and development route. Here we report a new approach, called DREAM-in-CDM (Drug Repurposing Effort Applying Integrated Modeling-in vitro/vivo-Clinical Data Mining), to identify an FDA-approved drug suitable for use as an effective analgesic targeting mPGES-1. The DREAM-in-CDM approach consists of three steps: computational screening of FDA-approved drugs; in vitro and/or in vivo assays; and clinical data mining. By using the DREAM-in-CDM approach, lapatinib has been identified as a promising mPGES-1 inhibitor which may have significant anti-inflammatory effects to relieve various forms of pain and possibly treat various inflammation conditions involved in other inflammation-related diseases such as the lung inflammation caused by the newly identified COVID-19. We anticipate that the DREAM-in-CDM approach will be used to repurpose FDA-approved drugs for various new therapeutic indications associated with new targets.Shuo ZhouZiyuan ZhouKai DingYaxia YuanCharles LoftinFang ZhengChang-Guo ZhanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shuo Zhou Ziyuan Zhou Kai Ding Yaxia Yuan Charles Loftin Fang Zheng Chang-Guo Zhan DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1
description	Abstract Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES-1 inhibitor identified through traditional drug discovery and development route. Here we report a new approach, called DREAM-in-CDM (Drug Repurposing Effort Applying Integrated Modeling-in vitro/vivo-Clinical Data Mining), to identify an FDA-approved drug suitable for use as an effective analgesic targeting mPGES-1. The DREAM-in-CDM approach consists of three steps: computational screening of FDA-approved drugs; in vitro and/or in vivo assays; and clinical data mining. By using the DREAM-in-CDM approach, lapatinib has been identified as a promising mPGES-1 inhibitor which may have significant anti-inflammatory effects to relieve various forms of pain and possibly treat various inflammation conditions involved in other inflammation-related diseases such as the lung inflammation caused by the newly identified COVID-19. We anticipate that the DREAM-in-CDM approach will be used to repurpose FDA-approved drugs for various new therapeutic indications associated with new targets.
format	article
author	Shuo Zhou Ziyuan Zhou Kai Ding Yaxia Yuan Charles Loftin Fang Zheng Chang-Guo Zhan
author_facet	Shuo Zhou Ziyuan Zhou Kai Ding Yaxia Yuan Charles Loftin Fang Zheng Chang-Guo Zhan
author_sort	Shuo Zhou
title	DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1
title_short	DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1
title_full	DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1
title_fullStr	DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1
title_full_unstemmed	DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1
title_sort	dream-in-cdm approach and identification of a new generation of anti-inflammatory drugs targeting mpges-1
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/6b1699a55ab84411a029ef331c7ca2c5
work_keys_str_mv	AT shuozhou dreamincdmapproachandidentificationofanewgenerationofantiinflammatorydrugstargetingmpges1 AT ziyuanzhou dreamincdmapproachandidentificationofanewgenerationofantiinflammatorydrugstargetingmpges1 AT kaiding dreamincdmapproachandidentificationofanewgenerationofantiinflammatorydrugstargetingmpges1 AT yaxiayuan dreamincdmapproachandidentificationofanewgenerationofantiinflammatorydrugstargetingmpges1 AT charlesloftin dreamincdmapproachandidentificationofanewgenerationofantiinflammatorydrugstargetingmpges1 AT fangzheng dreamincdmapproachandidentificationofanewgenerationofantiinflammatorydrugstargetingmpges1 AT changguozhan dreamincdmapproachandidentificationofanewgenerationofantiinflammatorydrugstargetingmpges1
_version_	1718379592848244736

DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1

Ejemplares similares